Skip to main content
    N

    Neuropace Inc (NPCE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $12.50
    -0.19 (-1.50%)

    Market Cap: $457.89M

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(15/22)
    Avg Surprise
    -519.63%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.15 - $-0.05
    8 analysts
    EPS Revisions
    4
    0
    7d
    3
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.10+14.9%
    60d ago$-0.09-1.4%
    30d ago$-0.090.0%
    7d ago$-0.090.0%
    Current$-0.09
    Revenue Consensus
    $27M
    Range$26M - $28M
    10 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.07
    Range$-0.16 - $0.16
    9 analysts
    Revenue Consensus
    $29M
    Range$28M - $30M
    10 analysts
    Last 12 of 23 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.07$-0.16 - $0.16--9--
    Sep 26EST
    		-$-0.09$-0.15 - $-0.05--8
    3
    2
    30d
    		-
    Jun 26
    Reported Aug 11
    		$-0.18$-0.19$-0.26 - $-0.15+5.26%Beat8
    2
    0
    30d
    		+30.8%
    Mar 26
    Reported May 12
    		$-0.20$-0.23$-0.29 - $-0.18+13.59%Beat6
    3
    2
    30d
    		+5.5%
    Dec 25
    Reported Mar 3
    		$-0.08$-0.15$-0.19 - $-0.10+46.67%Beat7
    4
    0
    30d
    		+55.6%
    Sep 25
    Reported Nov 4
    		$-0.11$-0.19$-0.23 - $-0.16+42.11%Beat7
    3
    2
    30d
    		+42.1%
    Jun 25
    Reported Aug 12
    		$-0.26$-0.22$-0.27 - $-0.17-18.18%Miss7
    4
    2
    30d
    		+0.0%
    Mar 25
    Reported May 13
    		$-0.21$-0.24$-0.31 - $-0.17+12.50%Beat6
    4
    1
    30d
    		+34.4%
    Dec 24
    Reported Mar 4
    		$-0.18$-0.22$-0.27 - $-0.18+19.39%Beat6
    1
    0
    30d
    		+21.7%
    Sep 24
    Reported Nov 12
    		$-0.19$-0.27$-0.29 - $-0.24+29.63%Beat6
    No revisions (30d)
    		+32.1%
    Jun 24
    Reported Aug 13
    		$-0.26$-0.30$-0.32 - $-0.26+13.33%Beat6
    No revisions (30d)
    		+27.8%
    Mar 24
    Reported May 8
    		$-0.32$-0.32$-0.38 - $-0.26+0.00%Beat6
    No revisions (30d)
    		+22.0%
    Dec 23
    Reported Mar 5
    		$-0.23$-0.32$-0.36 - $-0.25+28.13%Beat6
    No revisions (30d)
    		+48.9%
    Sep 23
    Reported Nov 6
    		$-0.28$-0.41$-0.44 - $-0.39+31.71%Beat4
    No revisions (30d)
    		+41.7%

    Key Metrics

    Valuation
    P/E Ratio-21.99EV/EBITDAN/A
    Price/FCF-36.72xFCF Yield-2.72%
    Profitability
    Profit Margin-17.90%Operating Margin-22.50%
    ROE-103.30%ROIC-16.94%
    Financial Health
    Debt/Equity4.97xInterest Coverage-2.41x
    Current Ratio4.94xQuick Ratio3.91x
    Trading Statistics
    Beta1.93Avg Volume111.45K
    52-Week High$19.6052-Week Low$12.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.74
    SMA 20$12.80
    SMA 50$13.52
    SMA 200$14.87
    EMA 10$12.73
    EMA 20$12.86
    EMA 50$13.39
    EMA 200$14.23

    MACD

    Line: -0.22Signal: -0.24Hist: 0.03

    ADX

    ADX: 11.9+DI: 20.9-DI: 22.2

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down88.0
    PSAR$12.08

    Bollinger Bands

    Upper Band$13.51
    Lower Band$12.10
    %B Position1101%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    44.4

    Momentum Oscillators

    Stoch %K43.5
    Stoch %D39.4
    Williams %R-74.2
    ROC (10d)-3.2%
    Momentum-0.41
    CCI (20d)-79.2
    MFI (14d)36.1

    Volatility Measures

    ATR (14d)$0.68(5.5%)
    StdDev (20d)0.35
    Hist Vol55.1%(High)

    Volume Flow

    VWAP$12.55
    OBV4.4M
    AD Line1.9M
    CMF (20d)-0.194

    Volume Metrics

    Avg Vol (20d)111.8K
    Vol Ratio1.1x
    VWMA (20d)$12.79

    Pivot Points

    R3$14.28
    R2$13.84
    R1$13.27
    Pivot Point$12.83
    S1$12.26
    S2$11.82
    S3$11.25

    Advanced Oscillators

    TSI-9.98
    Ultimate Osc38.2
    KST-49.73

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$22.83M$22.07M$26.59M$27.35M$19.50M$22.52M$21.47M$21.06M$19.26M$18.12M$18.01M$16.43M
    Cost of Revenue$3.92M$4.02M$6.01M$6.19M$3.29M$5.18M$5.28M$5.64M$5.12M$4.78M$4.47M$4.19M
    Gross Profit$18.91M$18.05M$20.58M$21.17M$16.21M$17.34M$16.19M$15.42M$14.13M$13.34M$13.54M$12.23M
    Operating Expenses$24.05M$23.62M$22.34M$23.77M$24.40M$22.49M$19.84M$19.66M$20.36M$20.89M$18.60M$18.18M
    R&D$6.90M$7.19M$7.03M$6.58M$6.84M$7.44M$6.05M$5.75M$6.07M$5.78M$5.38M$4.79M
    SG&A$5.03M$4.84M$-6,621,000$4.59M$6.07M$4.05M$-6,193,000$3.98M$4.54M$15.10M$13.22M$13.39M
    Operating Income$-5,143,000$-5,568,000$-1,767,000$-2,600,000$-8,189,000$-5,147,000$-3,653,000$-4,243,000$-6,230,000$-7,545,000$-5,051,000$-5,950,000
    Interest Income$523,000$565,000$638,000$667,000$718,000$793,000$681,000$754,000$762,000$827,000$822,000$769,000
    Interest Expense$1.54M$1.52M$1.60M$1.65M$2.06M$2.15M$2.19M$2.18M$2.17M$2.26M$2.24M$2.19M
    Income Before Tax$-6,200,000$-6,689,000$-2,729,000$-3,496,000$-10,016,000$-6,589,000$-5,250,000$-5,452,000$-7,514,000$-8,925,000$-6,200,000$-7,257,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,200,000$-6,689,000$-2,729,000$-3,496,000$-8,651,000$-6,589,000$-5,250,000$-5,452,000$-7,514,000$-8,925,000$-6,200,000$-7,257,000
    EBITDA$-4,584,000$-5,152,000$-1,182,000$-1,961,000$-8,143,000$-4,718,000$-3,239,000$-3,526,000$-5,612,000$-6,993,000$-4,301,000$-5,363,000
    EBIT$-5,184,000$-5,733,000$-1,767,000$-2,518,000$-8,675,000$-5,229,000$-3,739,000$-4,024,000$-6,110,000$-7,494,000$-4,786,000$-5,835,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NPCE

    Government Contracts

    Gov Obligations (TTM)
    $499896
    Gov Obligations / Revenue
    0.5%
    Obligations YoY
    N/A
    Active Awards
    11
    New Awards (TTM)
    11
    Avg Remaining Term
    3.4 mo

    Top agency: Department of Veterans Affairs at 52.8% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75N90026P00037Department of Health and Human ServicesNational Institutes of Health$115286Dec 30, 2025
    75N90025P00791Department of Health and Human ServicesNational Institutes of Health$60325Sep 28, 2025
    36C25626P0759Department of Veterans AffairsDepartment of Veterans Affairs$47970Jun 4, 2026
    36C25626P0449Department of Veterans AffairsDepartment of Veterans Affairs$47970Mar 5, 2026
    36C25626P0201Department of Veterans AffairsDepartment of Veterans Affairs$47020Nov 21, 2025
    36C25625P1741Department of Veterans AffairsDepartment of Veterans Affairs$47020Sep 19, 2025
    36C26226P0305Department of Veterans AffairsDepartment of Veterans Affairs$37600Dec 17, 2025
    36C24626P0485Department of Veterans AffairsDepartment of Veterans Affairs$36310Mar 11, 2026
    75N90025P00724Department of Health and Human ServicesNational Institutes of Health$25395Sep 15, 2025
    75N90026P00006Department of Health and Human ServicesNational Institutes of Health$18995Nov 6, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    NeuroPace Must Show Core RNS Strength Can Carry The Story While IGE Approval Stalls

    NeuroPace (NPCE) is facing a critical juncture as it heads into its third-quarter report. While its core RNS business for adult focal epilepsy continues to grow at about 20% with improving margins...

    Finviz•11/4/26•Somewhat-Bearish

    Understanding the Setup: (NPCE) and Scalable Risk

    This article provides a detailed analysis of Neuropace Inc. (NASDAQ: NPCE), highlighting weak near-term sentiment and a significant risk-reward setup. It outlines three AI-generated institutional trading...

    Stock Traders Daily•11/2/26•Somewhat-Bearish

    Press Release: NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026

    NeuroPace (NPCE) is scheduled to report its third-quarter 2026 financial results on November 12, 2026. This announcement comes from Dow Jones and was published on October 30...

    Moomoo•10/30/26•Neutral

    NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026

    NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its third-quarter 2026 financial results after market close on Thursday, November 12...

    Yahoo Finance•10/30/26•Neutral

    NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026

    NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its third-quarter 2026 financial results after market close on Thursday, November 12...

    StreetInsider•10/29/26•Neutral

    NPCE Valuation and Fair Value

    P/E
    -22.0x
    Forward P/E
    137.0x
    P/FCF
    -36.7x
    P/B
    35.9x
    See GNG's fair value

    NPCE Profitability: Margins, ROIC and FCF

    Gross margin
    79.6%
    Operating margin
    -22.5%
    Net margin
    -17.9%
    ROIC
    -16.9%
    ROE
    -103.3%
    FCF yield
    -2.7%

    NPCE Competitors

    CompanyTicker
    Strata Critical Medical, Inc.SRTA
    Alpha Teknova IncTKNO
    Senseonics Holdings, Inc. Common StockSENS
    Evolus IncEOLS
    XOMA CorpXOMA
    ProKidney Corp.PROK
    MiMedx Group IncMDXG
    Indaptus Therapeutics IncINDP

    Sector: Healthcare

    NPCE Analyst Ratings

    Consensus
    Buy
    Analysts
    10
    Strong Buy
    1
    Buy
    9
    Hold
    0
    Sell
    0
    Strong Sell
    0

    NPCE Bull Case vs Bear Case

    Bull case

    • NPCE beat EPS estimates in 87.5% of its last 8 reported quarters.
    • NPCE grew quarterly revenue 17.1% year over year.
    • 100.0% of NPCE's analyst ratings are Buy or Strong Buy.

    Bear case

    • NPCE has a -17.9% net profit margin.
    • NPCE has a debt-to-equity ratio of 5.0x.

    NPCE Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    18.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.09
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 2 down

    NPCE Earnings Date

    NPCE reports Nov 12, 2026, after the close. The date is confirmed.

    NPCE Earnings Call

    The latest NPCE earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    NPCE ETF Holders

    GNG tracks 5 ETFs that hold NPCE. The largest weights:

    1. State Street SPDR S&P Health Care Equipment ETF (XHE), 0.33% of the fund
    2. iShares Russell 2000 ETF (IWM), 0.02% of the fund
    3. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
    4. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    5. Vanguard Extended Market Index Fund ETF Shares (VXF), <0.01% of the fund
    Open the ETF Stock Exposure tool for NPCE

    See insider activity

    Frequently Asked Questions About NPCE

    When does NPCE report earnings?

    Neuropace Inc (NPCE) is confirmed to report earnings on Nov 12, 2026.

    Does NPCE pay dividends?

    Neuropace Inc (NPCE) does not currently pay a regular dividend.

    What is NPCE's market cap?

    Neuropace Inc (NPCE) has a market capitalization of $457.89M with a current stock price of $12.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In